NasdaqGS:TARSPharmaceuticals
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next
Tarsus Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$173.91 million versus US$102.66 million a year earlier, with net loss narrowing to US$18.55 million and loss per share from continuing operations improving to US$0.43.
Alongside these results, the company raised its 2026 XDEMVY net product sales guidance to a higher US$685 million–US$705 million range, signaling management’s increased confidence in the product’s commercial trajectory.
We’ll now...